Screener
Mirum Pharmaceuticals, Inc. MIRM Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Mirum Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsFairValueDisclosure.
The source filing: Mirum Pharmaceuticals, Inc.’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 5, 2026, 4:06 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001759425-26-000045
FAQ
- What is Mirum Pharmaceuticals, Inc.'s cash & equivalents?
- Mirum Pharmaceuticals, Inc. (MIRM) reported cash & equivalents of $262.68M in Q2 2026.
- How has Mirum Pharmaceuticals, Inc.'s cash & equivalents changed year-over-year?
- Mirum Pharmaceuticals, Inc.'s cash & equivalents increased by 39.4% year-over-year, from $188.37M to $262.68M.
- What is the long-term trend for Mirum Pharmaceuticals, Inc.'s cash & equivalents?
- Over 5 years (2020 to 2025), Mirum Pharmaceuticals, Inc.'s cash & equivalents has grown at a 12.4% compound annual growth rate (CAGR), from $142.09M to $254.38M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about Mirum Pharmaceuticals, Inc.'s cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude